The European Medicines Agency (EMA) has accepted for review an application seeking approval of the experimental injection therapy obexelimab for people with  immunoglobulin G4-related disease (IgG4-RD). The agency confirmed that the Marketing Authorization Application (MAA) submitted by the therapy’s developer, Zenas Biopharma, contains all the required information…
Discussion
Note: This column describes the author’s own experiences with Rituxan (rituximab). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. It may seem strange, and it certainly feels strange, to miss having a five-hour infusion that completely depletes your B-cells and…
Discussion
The approved therapy Uplizna (inebilizumab) may reduce the risk of disease flares in adults with IgG4-related disease (IgG4-RD) who have kidney involvement, according to a new analysis of clinical trial data. The new analysis focuses on a subgroup of patients in the Phase 3 MITIGATE clinical trial…
Get regular updates to your inbox.
